View in EDS HTML Full Text PDF Full Text

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.

Saved in:
Bibliographic Details
Title: Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
Authors: Piha-Paul SA; University of Texas MD Anderson Cancer Center, Houston, TX., Hann CL; Johns Hopkins University School of Medicine, Baltimore, MD., French CA; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA., Cousin S; Medical Oncology, Institute Bergonié, Bordeaux, France., Braña I; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Cassier PA; Medical Oncology, Léon Bérard Cancer Center, Lyon, France., Moreno V; Medical Oncology, START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, Spain., de Bono JS; The Institute of Cancer Research and Royal Marsden Hospital, London, UK., Harward SD; GSK, Research Triangle Park, NC., Ferron-Brady G; GSK, Collegeville, PA., Barbash O; GSK, Collegeville, PA., Wyce A; GSK, Collegeville, PA., Wu Y; GSK, Collegeville, PA., Horner T; GSK, Collegeville, PA., Annan M; GSK, Collegeville, PA., Parr NJ; UCB Celltech, Slough, UK., Prinjha RK; Division of Medical Oncology, Ottawa Hospital Cancer Centre, Ottawa, ON, Canada., Carpenter CL; Rubius Therapeutics, Cambridge, MA., Hilton J; Division of Medical Oncology, Ottawa Hospital Cancer Centre, Ottawa, ON, Canada., Hong DS; University of Texas MD Anderson Cancer Center, Houston, TX.; Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.; Medical Oncology, Institute Bergonié, Bordeaux, France.; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Medical Oncology, Léon Bérard Cancer Center, Lyon, France.; Medical Oncology, START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, Spain.; The Institute of Cancer Research and Royal Marsden Hospital, London, UK.; GSK, Research Triangle Park, NC.; GSK, Collegeville, PA.; UCB Celltech, Slough, UK.; Division of Medical Oncology, Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.; Rubius Therapeutics, Cambridge, MA.; Abramson Cancer Center at University of Pennsylvania, Philadelphia, PA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Haas NB; Abramson Cancer Center at University of Pennsylvania, Philadelphia, PA., Markowski MC; Johns Hopkins University School of Medicine, Baltimore, MD., Dhar A; GSK, Collegeville, PA., O'Dwyer PJ; University of Texas MD Anderson Cancer Center, Houston, TX.; Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.; Medical Oncology, Institute Bergonié, Bordeaux, France.; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Medical Oncology, Léon Bérard Cancer Center, Lyon, France.; Medical Oncology, START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, Spain.; The Institute of Cancer Research and Royal Marsden Hospital, London, UK.; GSK, Research Triangle Park, NC.; GSK, Collegeville, PA.; UCB Celltech, Slough, UK.; Division of Medical Oncology, Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.; Rubius Therapeutics, Cambridge, MA.; Abramson Cancer Center at University of Pennsylvania, Philadelphia, PA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Source: JNCI cancer spectrum [JNCI Cancer Spectr] 2019 Nov 06; Vol. 4 (2), pp. pkz093. Date of Electronic Publication: 2019 Nov 06 (Print Publication: 2020).
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101721827 Publication Model: eCollection Cited Medium: Internet ISSN: 2515-5091 (Electronic) Linking ISSN: 25155091 NLM ISO Abbreviation: JNCI Cancer Spectr Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32328561
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Piha-Paul+SA%22">Piha-Paul SA</searchLink>; University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Hann+CL%22">Hann CL</searchLink>; Johns Hopkins University School of Medicine, Baltimore, MD.<br /><searchLink fieldCode="AU" term="%22French+CA%22">French CA</searchLink>; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Cousin+S%22">Cousin S</searchLink>; Medical Oncology, Institute Bergonié, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Braña+I%22">Braña I</searchLink>; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Cassier+PA%22">Cassier PA</searchLink>; Medical Oncology, Léon Bérard Cancer Center, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Moreno+V%22">Moreno V</searchLink>; Medical Oncology, START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22de+Bono+JS%22">de Bono JS</searchLink>; The Institute of Cancer Research and Royal Marsden Hospital, London, UK.<br /><searchLink fieldCode="AU" term="%22Harward+SD%22">Harward SD</searchLink>; GSK, Research Triangle Park, NC.<br /><searchLink fieldCode="AU" term="%22Ferron-Brady+G%22">Ferron-Brady G</searchLink>; GSK, Collegeville, PA.<br /><searchLink fieldCode="AU" term="%22Barbash+O%22">Barbash O</searchLink>; GSK, Collegeville, PA.<br /><searchLink fieldCode="AU" term="%22Wyce+A%22">Wyce A</searchLink>; GSK, Collegeville, PA.<br /><searchLink fieldCode="AU" term="%22Wu+Y%22">Wu Y</searchLink>; GSK, Collegeville, PA.<br /><searchLink fieldCode="AU" term="%22Horner+T%22">Horner T</searchLink>; GSK, Collegeville, PA.<br /><searchLink fieldCode="AU" term="%22Annan+M%22">Annan M</searchLink>; GSK, Collegeville, PA.<br /><searchLink fieldCode="AU" term="%22Parr+NJ%22">Parr NJ</searchLink>; UCB Celltech, Slough, UK.<br /><searchLink fieldCode="AU" term="%22Prinjha+RK%22">Prinjha RK</searchLink>; Division of Medical Oncology, Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Carpenter+CL%22">Carpenter CL</searchLink>; Rubius Therapeutics, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Hilton+J%22">Hilton J</searchLink>; Division of Medical Oncology, Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Hong+DS%22">Hong DS</searchLink>; University of Texas MD Anderson Cancer Center, Houston, TX.; Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.; Medical Oncology, Institute Bergonié, Bordeaux, France.; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Medical Oncology, Léon Bérard Cancer Center, Lyon, France.; Medical Oncology, START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, Spain.; The Institute of Cancer Research and Royal Marsden Hospital, London, UK.; GSK, Research Triangle Park, NC.; GSK, Collegeville, PA.; UCB Celltech, Slough, UK.; Division of Medical Oncology, Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.; Rubius Therapeutics, Cambridge, MA.; Abramson Cancer Center at University of Pennsylvania, Philadelphia, PA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Haas+NB%22">Haas NB</searchLink>; Abramson Cancer Center at University of Pennsylvania, Philadelphia, PA.<br /><searchLink fieldCode="AU" term="%22Markowski+MC%22">Markowski MC</searchLink>; Johns Hopkins University School of Medicine, Baltimore, MD.<br /><searchLink fieldCode="AU" term="%22Dhar+A%22">Dhar A</searchLink>; GSK, Collegeville, PA.<br /><searchLink fieldCode="AU" term="%22O'Dwyer+PJ%22">O'Dwyer PJ</searchLink>; University of Texas MD Anderson Cancer Center, Houston, TX.; Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.; Medical Oncology, Institute Bergonié, Bordeaux, France.; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Medical Oncology, Léon Bérard Cancer Center, Lyon, France.; Medical Oncology, START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, Spain.; The Institute of Cancer Research and Royal Marsden Hospital, London, UK.; GSK, Research Triangle Park, NC.; GSK, Collegeville, PA.; UCB Celltech, Slough, UK.; Division of Medical Oncology, Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.; Rubius Therapeutics, Cambridge, MA.; Abramson Cancer Center at University of Pennsylvania, Philadelphia, PA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Shapiro+GI%22">Shapiro GI</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101721827%22">JNCI cancer spectrum</searchLink> [JNCI Cancer Spectr] 2019 Nov 06; Vol. 4 (2), pp. pkz093. <i>Date of Electronic Publication: </i>2019 Nov 06 (<i>Print Publication: </i>2020).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101721827 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2515-5091 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225155091%22">25155091 </searchLink><i>NLM ISO Abbreviation: </i>JNCI Cancer Spectr <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32328561
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/jncics/pkz093
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: pkz093
    Titles:
      – TitleFull: Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Piha-Paul SA
      – PersonEntity:
          Name:
            NameFull: Hann CL
      – PersonEntity:
          Name:
            NameFull: French CA
      – PersonEntity:
          Name:
            NameFull: Cousin S
      – PersonEntity:
          Name:
            NameFull: Braña I
      – PersonEntity:
          Name:
            NameFull: Cassier PA
      – PersonEntity:
          Name:
            NameFull: Moreno V
      – PersonEntity:
          Name:
            NameFull: de Bono JS
      – PersonEntity:
          Name:
            NameFull: Harward SD
      – PersonEntity:
          Name:
            NameFull: Ferron-Brady G
      – PersonEntity:
          Name:
            NameFull: Barbash O
      – PersonEntity:
          Name:
            NameFull: Wyce A
      – PersonEntity:
          Name:
            NameFull: Wu Y
      – PersonEntity:
          Name:
            NameFull: Horner T
      – PersonEntity:
          Name:
            NameFull: Annan M
      – PersonEntity:
          Name:
            NameFull: Parr NJ
      – PersonEntity:
          Name:
            NameFull: Prinjha RK
      – PersonEntity:
          Name:
            NameFull: Carpenter CL
      – PersonEntity:
          Name:
            NameFull: Hilton J
      – PersonEntity:
          Name:
            NameFull: Hong DS
      – PersonEntity:
          Name:
            NameFull: Haas NB
      – PersonEntity:
          Name:
            NameFull: Markowski MC
      – PersonEntity:
          Name:
            NameFull: Dhar A
      – PersonEntity:
          Name:
            NameFull: O'Dwyer PJ
      – PersonEntity:
          Name:
            NameFull: Shapiro GI
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 06
              M: 11
              Text: 2019 Nov 06
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-electronic
              Value: 2515-5091
          Numbering:
            – Type: volume
              Value: 4
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: JNCI cancer spectrum
              Type: main
ResultId 1